IS5000A - Heteróarýl súkkínamíð og notkun þeirra sem málmprótínasa tálma - Google Patents

Heteróarýl súkkínamíð og notkun þeirra sem málmprótínasa tálma

Info

Publication number
IS5000A
IS5000A IS5000A IS5000A IS5000A IS 5000 A IS5000 A IS 5000A IS 5000 A IS5000 A IS 5000A IS 5000 A IS5000 A IS 5000A IS 5000 A IS5000 A IS 5000A
Authority
IS
Iceland
Prior art keywords
succinamide
heteroaryl
proteinase inhibitor
metal proteinase
metal
Prior art date
Application number
IS5000A
Other languages
English (en)
Inventor
L. Bender Steven
L. Castelhano Arlindo
K.M. Chong Wesley
A. Abreo Melwyn
L. Billedeau Roland
Jeffrey Chen Jian
G. Deal Judith
Original Assignee
Agouron Pharmaceuticals, Inc.
Syntex (U.S.A.) Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc., Syntex (U.S.A.) Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of IS5000A publication Critical patent/IS5000A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IS5000A 1996-10-24 1999-03-12 Heteróarýl súkkínamíð og notkun þeirra sem málmprótínasa tálma IS5000A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2911596P 1996-10-24 1996-10-24
US08/823,962 US6008243A (en) 1996-10-24 1997-03-25 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
PCT/US1997/017809 WO1998017643A1 (en) 1996-10-24 1997-10-06 Heteroaryl succinamides and their use as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
IS5000A true IS5000A (is) 1999-03-12

Family

ID=26704557

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5000A IS5000A (is) 1996-10-24 1999-03-12 Heteróarýl súkkínamíð og notkun þeirra sem málmprótínasa tálma

Country Status (25)

Country Link
US (1) US6008243A (is)
EP (1) EP0937042A1 (is)
JP (1) JP2000511201A (is)
KR (1) KR20000052779A (is)
CN (1) CN1233237A (is)
AP (1) AP1360A (is)
AR (1) AR009124A1 (is)
AU (1) AU735194C (is)
BG (1) BG64506B1 (is)
BR (1) BR9713278A (is)
CA (1) CA2267879C (is)
CZ (1) CZ132199A3 (is)
EA (1) EA003127B1 (is)
EE (1) EE9900171A (is)
GE (1) GEP20012578B (is)
IL (1) IL128914A (is)
IS (1) IS5000A (is)
NO (1) NO313281B1 (is)
NZ (1) NZ334886A (is)
OA (1) OA11035A (is)
PL (1) PL332947A1 (is)
SK (1) SK48499A3 (is)
TR (2) TR199900874T2 (is)
WO (1) WO1998017643A1 (is)
YU (1) YU20199A (is)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP980443A2 (en) * 1997-08-18 1999-10-31 Carl P. Decicco Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
CA2315370A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
WO1999041232A1 (en) * 1998-02-13 1999-08-19 British Biotech Pharmaceuticals Limited Cytostatic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6934639B1 (en) * 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
BR0207209A (pt) * 2001-02-14 2004-01-27 Warner Lambert Co Inibidores de metaloproteinase de matriz de pirimidina
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
EP1434585A1 (en) 2001-10-12 2004-07-07 Warner-Lambert Company LLC Alkyne matrix metalloproteinase inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US6667330B2 (en) * 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
MXPA05000723A (es) * 2002-07-17 2005-04-08 Warner Lambert Co Combinacion de un inhibidor alosterico de metaloproteinasa-13 de matriz con un inhibidor selectivo de ciclooxigenasa-2 que no es celecoxib o valdecoxib.
WO2004007025A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
EP1534274A1 (en) * 2002-07-17 2005-06-01 Warner-Lambert Company LLC Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
JP2006503812A (ja) * 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブではない選択的シクロオキシゲナーゼ−２阻害薬との組み合わせ
JP2006503008A (ja) * 2002-08-13 2006-01-26 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体
AU2003250471A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
EP1537098A1 (en) * 2002-08-13 2005-06-08 Warner-Lambert Company LLC Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003249531A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003250466A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014923A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2004014909A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
JP2005539020A (ja) * 2002-08-13 2005-12-22 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としてのクロモン誘導体
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2004014375A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US8691835B2 (en) * 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
MX2009013240A (es) * 2007-06-05 2010-01-25 Pfizer Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones.
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
MX2013012542A (es) * 2011-04-28 2013-11-20 Japan Tobacco Inc Compuestos de amida y aplicacion farmaceutica para el mismo.
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents
CN104926707B (zh) * 2015-05-12 2017-10-27 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN106749128A (zh) * 2017-01-13 2017-05-31 滕州市悟通香料有限责任公司 一种制备2‑甲基‑3‑巯基呋喃的方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
EP0489579B1 (en) * 1990-12-03 1995-03-29 Celltech Therapeutics Limited Peptidyl derivatives
CA2102890A1 (en) * 1991-05-28 1992-11-29 Soumya P. Sahoo Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5376664A (en) * 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
JPH08503475A (ja) * 1992-11-25 1996-04-16 メルク エンド カンパニー インコーポレーテッド 抗変性活性剤としてのカルボキシ−ペプチジル誘導体
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
ES2134939T3 (es) * 1993-04-27 1999-10-16 Celltech Therapeutics Ltd Derivados de peptidilo como inhibidores de metaloproteinas.
KR100347646B1 (ko) * 1993-08-05 2002-12-05 신텍스(미국) 인크. 매트릭스메탈로프로테아제억제제
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
CA2181709A1 (en) * 1994-01-22 1995-07-27 Raymond Paul Beckett Hydroxamic acid derivatives as metalloproteinase inhibitors
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
JPH10500986A (ja) * 1994-05-28 1998-01-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
ES2145913T3 (es) * 1994-06-22 2000-07-16 British Biotech Pharm Inhibidores de metaloproteasas.
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1996033172A1 (en) * 1995-04-20 1996-10-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
KR100231230B1 (ko) * 1995-08-08 1999-11-15 우에노 도시오 히드록삼산 유도체(hydroxamic acid derivatives)
RU2164914C2 (ru) * 1995-11-13 2001-04-10 Хехст Акциенгезелльшафт ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ
DE19542189A1 (de) * 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
ES2184893T3 (es) * 1995-11-17 2003-04-16 Warner Lambert Co Inhibidores de sulfonamida de lasd metaloproteinasas matricales.
ES2195034T3 (es) * 1995-12-08 2003-12-01 Agouron Pharma Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
ATE214368T1 (de) * 1995-12-22 2002-03-15 Warner Lambert Co Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
KR100338857B1 (ko) * 1996-01-23 2002-05-30 시오노 요시히코 술폰화 아미노산 유도체 및 이를 함유한메탈로프로테이나제 저해제
JP2000501423A (ja) * 1996-08-23 2000-02-08 ファイザー インク． アリールスルホニルアミノヒドロキサム酸誘導体
TR199900431T2 (xx) * 1996-08-28 1999-04-21 The Procter & Gamble Company �kame edilmi� siklik amin metaloproteaz inhibit�rleri
NZ334253A (en) * 1996-08-28 2000-11-24 Procter & Gamble N-hydroxy 1-[(4-methoxyphenyl)sulfonyl]-4-benzyloxycarbonyl-piperazine 2-carboxamide and derivatives thereof for treating musculoskeletal disease or cachexia

Also Published As

Publication number Publication date
NO991922L (no) 1999-04-22
NZ334886A (en) 2000-11-24
CA2267879C (en) 2006-03-14
AU735194C (en) 2002-08-08
EP0937042A1 (en) 1999-08-25
AR009124A1 (es) 2000-03-08
GEP20012578B (en) 2001-11-26
SK48499A3 (en) 2000-04-10
KR20000052779A (ko) 2000-08-25
TR200402157T2 (tr) 2005-02-21
IL128914A (en) 2003-04-10
PL332947A1 (en) 1999-10-25
TR199900874T2 (xx) 1999-07-21
BG64506B1 (bg) 2005-05-31
NO991922D0 (no) 1999-04-22
US6008243A (en) 1999-12-28
AU4806097A (en) 1998-05-15
NO313281B1 (no) 2002-09-09
JP2000511201A (ja) 2000-08-29
AP9901536A0 (en) 1999-06-30
AP1360A (en) 2005-01-05
EE9900171A (et) 1999-12-15
EA199900366A1 (ru) 1999-10-28
BR9713278A (pt) 1999-11-03
YU20199A (sh) 2001-09-28
AU735194B2 (en) 2001-07-05
CA2267879A1 (en) 1998-04-30
IL128914A0 (en) 2000-02-17
CN1233237A (zh) 1999-10-27
BG103415A (en) 2000-07-31
OA11035A (en) 2002-03-06
EA003127B1 (ru) 2003-02-27
CZ132199A3 (cs) 1999-09-15
WO1998017643A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
IS5000A (is) Heteróarýl súkkínamíð og notkun þeirra sem málmprótínasa tálma
DE69711222D1 (de) Aminoguanidine und alkoxyguanidine als protease-hemmer
PL357713A1 (en) Caspase inhibitors and uses thereof
TWI318207B (en) Carbamate caspase inhibitors and uses thereof
NO942247L (no) Korrosjonsinhibitor og anvendelse derav
PL340560A1 (en) Heteroaryl aminoguanidines and alkoxyguanidines and their application as protease inhibitors
ID19198A (id) Inhibitor metaloprotease heterosiklik
ID18416A (id) Inhibitor metaloprotease diheterosiklik
IS4930A (is) Nýjar amidínóafleiður og notkun þeirra sem þrombínhemla
PL356066A1 (en) Caspase inhibitors and uses thereof
SI1251848T1 (en) Gyrase inhibitors and uses thereof
HUP9900666A3 (en) Phosphodiesterase inhibitor phenanthridines derivatives and use thereof
IS6700A (is) Meðferðarblanda CETP hindra og atórvastatíns
HUP0000427A3 (en) Benzamidoaldehydes and their use as cysteine protease inhibitors
HUP0104500A3 (en) Thrombin inhibitor dipeptide derivatives and their use
ID18141A (id) Inhibitor metaloprotease 1,3-diheterosiklik
PL369855A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
IS5302A (is) Nýjar amidínóafleiður og notkun þeirra sem þrombínhemla
NO20005196L (no) Substituerte pyrrolidinhydroksamat-metallproteaseinhibitorer
NO986049D0 (no) Matrise metallproteinase inhibitorer
GB9716987D0 (en) Low toxic corrosion inhibitor
IS4312A (is) Skvalen lígasa efnahemlar og notkun theirra
DK1015419T3 (da) Polydentate iminer og deres metalkomplekser
HU9603406D0 (en) Reswitching inhibitor
AU3721000A (en) Corrosion inhibitor and process